SARS-CoV-2 variant Alpha has a spike-dependent replication advantage over the ancestral B.1 strain in human cells with low ACE2 expression.
Journal
PLoS biology
ISSN: 1545-7885
Titre abrégé: PLoS Biol
Pays: United States
ID NLM: 101183755
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
11
11
2021
accepted:
06
10
2022
revised:
30
11
2022
pubmed:
17
11
2022
medline:
3
12
2022
entrez:
16
11
2022
Statut:
epublish
Résumé
Epidemiological data demonstrate that Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) Alpha and Delta are more transmissible, infectious, and pathogenic than previous variants. Phenotypic properties of VOC remain understudied. Here, we provide an extensive functional study of VOC Alpha replication and cell entry phenotypes assisted by reverse genetics, mutational mapping of spike in lentiviral pseudotypes, viral and cellular gene expression studies, and infectivity stability assays in an enhanced range of cell and epithelial culture models. In almost all models, VOC Alpha spread less or equally efficiently as ancestral (B.1) SARS-CoV-2. B.1. and VOC Alpha shared similar susceptibility to serum neutralization. Despite increased relative abundance of specific sgRNAs in the context of VOC Alpha infection, immune gene expression in infected cells did not differ between VOC Alpha and B.1. However, inferior spreading and entry efficiencies of VOC Alpha corresponded to lower abundance of proteolytically cleaved spike products presumably linked to the T716I mutation. In addition, we identified a bronchial cell line, NCI-H1299, which supported 24-fold increased growth of VOC Alpha and is to our knowledge the only cell line to recapitulate the fitness advantage of VOC Alpha compared to B.1. Interestingly, also VOC Delta showed a strong (595-fold) fitness advantage over B.1 in these cells. Comparative analysis of chimeric viruses expressing VOC Alpha spike in the backbone of B.1, and vice versa, showed that the specific replication phenotype of VOC Alpha in NCI-H1299 cells is largely determined by its spike protein. Despite undetectable ACE2 protein expression in NCI-H1299 cells, CRISPR/Cas9 knock-out and antibody-mediated blocking experiments revealed that multicycle spread of B.1 and VOC Alpha required ACE2 expression. Interestingly, entry of VOC Alpha, as opposed to B.1 virions, was largely unaffected by treatment with exogenous trypsin or saliva prior to infection, suggesting enhanced resistance of VOC Alpha spike to premature proteolytic cleavage in the extracellular environment of the human respiratory tract. This property may result in delayed degradation of VOC Alpha particle infectivity in conditions typical of mucosal fluids of the upper respiratory tract that may be recapitulated in NCI-H1299 cells closer than in highly ACE2-expressing cell lines and models. Our study highlights the importance of cell model evaluation and comparison for in-depth characterization of virus variant-specific phenotypes and uncovers a fine-tuned interrelationship between VOC Alpha- and host cell-specific determinants that may underlie the increased and prolonged virus shedding detected in patients infected with VOC Alpha.
Identifiants
pubmed: 36383605
doi: 10.1371/journal.pbio.3001871
pii: PBIOLOGY-D-21-02962
pmc: PMC9710838
doi:
Substances chimiques
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Antibodies, Blocking
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3001871Informations de copyright
Copyright: © 2022 Niemeyer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: Technische Universität Berlin, Freie Universität Berlin and Charité - Universitätsmedizin have filed a patent application for siRNAs inhibiting SARS-CoV-2 replication with DN as co-author. MAMü and VMC are named together with Charité - Universitätsmedizin Berlin and Euroimmun Medizinische Labordiagnostika AG on a patent application (EP3715847) filed recently regarding the diagnostic of SARS-CoV-2 by antibody testing. The other authors declare no competing interests.
Références
Cell Rep. 2020 Dec 8;33(10):108488
pubmed: 33271063
EMBO J. 2021 Dec 15;40(24):e108944
pubmed: 34601723
Clin Infect Dis. 2022 Aug 24;75(1):e1128-e1136
pubmed: 34423834
bioRxiv. 2021 Jun 07;:
pubmed: 34127972
Cell Rep. 2021 Jul 20;36(3):109415
pubmed: 34270919
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
Lancet Respir Med. 2021 Nov;9(11):1255-1265
pubmed: 34391547
Microbiol Spectr. 2022 Aug 31;10(4):e0151422
pubmed: 35766497
J Virol Methods. 2021 Feb;288:114031
pubmed: 33275926
Cell Stem Cell. 2020 Dec 3;27(6):905-919.e10
pubmed: 33142113
Nature. 2022 Feb;602(7897):487-495
pubmed: 34942634
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
EClinicalMedicine. 2021 Oct;40:101129
pubmed: 34541481
BMC Res Notes. 2016 Feb 12;9:88
pubmed: 26868221
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Nat Commun. 2021 Aug 26;12(1):5135
pubmed: 34446720
Gastroenterology. 2011 Nov;141(5):1762-72
pubmed: 21889923
J Infect Dis. 2021 Oct 13;224(7):1109-1114
pubmed: 34223909
Cell. 2020 Nov 12;183(4):1058-1069.e19
pubmed: 33058755
Nat Struct Mol Biol. 2021 Sep;28(9):731-739
pubmed: 34385690
Clin Infect Dis. 2022 Aug 24;75(1):e1120-e1127
pubmed: 34487522
Science. 2021 Dec 10;374(6573):1353-1360
pubmed: 34698504
Cell. 2020 Jul 23;182(2):429-446.e14
pubmed: 32526206
Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3
pubmed: 33705729
Nat Commun. 2020 Oct 12;11(1):5139
pubmed: 33046696
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Am J Respir Cell Mol Biol. 2017 May;56(5):568-574
pubmed: 27983869
Commun Biol. 2021 Sep 20;4(1):1102
pubmed: 34545191
Nat Microbiol. 2022 Aug;7(8):1161-1179
pubmed: 35798890
Mol Ther. 2006 Oct;14(4):555-63
pubmed: 16814610
Cell Rep. 2021 Jun 29;35(13):109292
pubmed: 34166617
Infection. 2021 Aug;49(4):703-714
pubmed: 33890243
Curr Opin Virol. 2021 Oct;50:49-58
pubmed: 34365113
Bioinformatics. 2011 Nov 1;27(21):2957-63
pubmed: 21903629
PLoS Pathog. 2020 Dec 7;16(12):e1009130
pubmed: 33284849
Virol J. 2010 Feb 26;7:50
pubmed: 20187932
J Virol. 2021 Mar 16;95(11):
pubmed: 33727331
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Cell Rep. 2021 Jul 13;36(2):109364
pubmed: 34214467
Cell Res. 2008 Feb;18(2):290-301
pubmed: 18227861
Science. 2021 Jul 9;373(6551):
pubmed: 34035154
Cell. 2021 Apr 15;184(8):2201-2211.e7
pubmed: 33743891
Cell Rep. 2022 May 17;39(7):110829
pubmed: 35550680
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Front Microbiol. 2021 Jul 29;12:701198
pubmed: 34394046
Nature. 2021 May;593(7858):270-274
pubmed: 33723411
mBio. 2021 Aug 31;12(4):e0085021
pubmed: 34225487
J Cell Biochem Suppl. 1996;24:32-91
pubmed: 8806092
Mol Syst Biol. 2020 Jul;16(7):e9610
pubmed: 32715618
N Engl J Med. 2021 Dec 23;385(26):2489-2491
pubmed: 34941024
Lancet. 2020 Aug 29;396(10251):603-611
pubmed: 32822564
mSphere. 2021 Jun 16;:e0050721
pubmed: 34133199
Nature. 2022 Feb;602(7896):300-306
pubmed: 34823256
EBioMedicine. 2021 Jun;68:103403
pubmed: 34049240
PLoS One. 2008 Apr 30;3(4):e2032
pubmed: 18446221
Emerg Microbes Infect. 2021 Dec;10(1):2173-2182
pubmed: 34724885
Nat Biotechnol. 1997 Sep;15(9):871-5
pubmed: 9306402
Nature. 2020 Jun;582(7813):561-565
pubmed: 32365353
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
Front Immunol. 2021 Jan 29;11:628971
pubmed: 33584731
Wellcome Open Res. 2021 May 19;6:121
pubmed: 34095513
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Cell Host Microbe. 2018 Dec 12;24(6):761-775.e6
pubmed: 30503508
Lancet Infect Dis. 2021 Aug;21(8):1070
pubmed: 34022142
Cell Host Microbe. 2021 Jul 14;29(7):1124-1136.e11
pubmed: 34171266
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225
iScience. 2022 Jan 21;25(1):103589
pubmed: 34909610
Science. 2022 Feb 18;375(6582):782-787
pubmed: 35076281
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
iScience. 2021 Mar 19;24(3):102151
pubmed: 33585804